Dainippon Sumitomo Pharma Enters into Partnership Agreement on Anti-Hypertension and Hepatocellular Cancer Drugs.Tokyo, Japan, July 26, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Dainippon Sumitomo Pharma (DSP (1) (Digital Signal Processor) A special-purpose CPU used for digital signal processing applications (see definition #2 below). It provides ultra-fast instruction sequences, such as shift and add, and multiply and add, which are commonly used in math-intensive ) and Bristol-Myers K.K. (BMKK) have concluded an agreement on the marketing rights of anti-hypertension and hepatocellular cancer drug. Under the agreement terms, BMKK will sublicense to DSP the development, manufacturing/marketing and marketing rights of irbesartan, an anti-hypertension drug. Respectively, DSP will grant BMKK with co-marketing rights of SM-11355 (generic name generic name n. 1. The official nonproprietary name of a drug, under which it is licensed and identified by the manufacturer. 2. : miriplatin hydrate hydrate (hī`drāt), chemical compound that contains water. A common hydrate is the familiar blue vitriol, a crystalline form of cupric sulfate. Chemically, it is cupric sulfate pentahydrate, CuSO4·5H2O. ), a therapeutic drug for hepatocellular carcinoma hep·a·to·cel·lu·lar carcinoma n. A carcinoma derived from parenchymal cells of the liver. Also called hepatocarcinoma, malignant hepatoma. . DSP expects the addition of irbesartan, which is currently under phase III trials in Japan, to further expand its line up of anti-hypertension drug. SM-11355 is now under phase II development in Japan as hepatic arterial injection chemotherapy in treating hepatocellular carcinoma. The agreement will enable both firms to co-market the drug, as soon as DSP obtains manufacturing and marketing approval. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion